Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients

Eishi Baba, Hiromitsu Fujishima, Akitaka Makiyama, Keita Uchino, Risa Tanaka, Taito Esaki, Hitoshi Kusaba, Kenji Mitsugi, Shuji Nakano, Koichi Akashi

Research output: Contribution to journalArticle

Abstract

Introduction: Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity. Methods: A total of 29 patients with metastatic colorectal cancer were included. Our modified Saltz regimen was administered. The primary endpoint was overall response rate. Results: Of the 29 patients, 11 had previous chemotherapy. A partial response occurred in 11 patients, stable disease in 16 patients, and progressive disease in two patients. Disease control rate was 93.1%. Response rates with and without previous treatment were 18.2% and 50%, respectively. Median progression-free survival was 17.3 months. The main hematologic toxicities were leukopenia (22.6%) and neutropenia (45.2%). No treatment-related deaths occurred. Conclusion: Our modified Saltz regimen exhibited sufficient efficacy, feasibility, and manageable toxicity as a therapeutic option for selected colorectal cancer patients.

Original languageEnglish
Pages (from-to)287-296
Number of pages10
JournalAdvances in Therapy
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 1 2012

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Drug Therapy
Leukopenia
Neutropenia
Disease-Free Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. / Baba, Eishi; Fujishima, Hiromitsu; Makiyama, Akitaka; Uchino, Keita; Tanaka, Risa; Esaki, Taito; Kusaba, Hitoshi; Mitsugi, Kenji; Nakano, Shuji; Akashi, Koichi.

In: Advances in Therapy, Vol. 29, No. 3, 01.03.2012, p. 287-296.

Research output: Contribution to journalArticle

Baba, Eishi ; Fujishima, Hiromitsu ; Makiyama, Akitaka ; Uchino, Keita ; Tanaka, Risa ; Esaki, Taito ; Kusaba, Hitoshi ; Mitsugi, Kenji ; Nakano, Shuji ; Akashi, Koichi. / Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. In: Advances in Therapy. 2012 ; Vol. 29, No. 3. pp. 287-296.
@article{dbcaa2cacee0480c9912c4f8226d0e8e,
title = "Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients",
abstract = "Introduction: Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity. Methods: A total of 29 patients with metastatic colorectal cancer were included. Our modified Saltz regimen was administered. The primary endpoint was overall response rate. Results: Of the 29 patients, 11 had previous chemotherapy. A partial response occurred in 11 patients, stable disease in 16 patients, and progressive disease in two patients. Disease control rate was 93.1{\%}. Response rates with and without previous treatment were 18.2{\%} and 50{\%}, respectively. Median progression-free survival was 17.3 months. The main hematologic toxicities were leukopenia (22.6{\%}) and neutropenia (45.2{\%}). No treatment-related deaths occurred. Conclusion: Our modified Saltz regimen exhibited sufficient efficacy, feasibility, and manageable toxicity as a therapeutic option for selected colorectal cancer patients.",
author = "Eishi Baba and Hiromitsu Fujishima and Akitaka Makiyama and Keita Uchino and Risa Tanaka and Taito Esaki and Hitoshi Kusaba and Kenji Mitsugi and Shuji Nakano and Koichi Akashi",
year = "2012",
month = "3",
day = "1",
doi = "10.1007/s12325-012-0002-3",
language = "English",
volume = "29",
pages = "287--296",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "3",

}

TY - JOUR

T1 - Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients

AU - Baba, Eishi

AU - Fujishima, Hiromitsu

AU - Makiyama, Akitaka

AU - Uchino, Keita

AU - Tanaka, Risa

AU - Esaki, Taito

AU - Kusaba, Hitoshi

AU - Mitsugi, Kenji

AU - Nakano, Shuji

AU - Akashi, Koichi

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Introduction: Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity. Methods: A total of 29 patients with metastatic colorectal cancer were included. Our modified Saltz regimen was administered. The primary endpoint was overall response rate. Results: Of the 29 patients, 11 had previous chemotherapy. A partial response occurred in 11 patients, stable disease in 16 patients, and progressive disease in two patients. Disease control rate was 93.1%. Response rates with and without previous treatment were 18.2% and 50%, respectively. Median progression-free survival was 17.3 months. The main hematologic toxicities were leukopenia (22.6%) and neutropenia (45.2%). No treatment-related deaths occurred. Conclusion: Our modified Saltz regimen exhibited sufficient efficacy, feasibility, and manageable toxicity as a therapeutic option for selected colorectal cancer patients.

AB - Introduction: Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity. Methods: A total of 29 patients with metastatic colorectal cancer were included. Our modified Saltz regimen was administered. The primary endpoint was overall response rate. Results: Of the 29 patients, 11 had previous chemotherapy. A partial response occurred in 11 patients, stable disease in 16 patients, and progressive disease in two patients. Disease control rate was 93.1%. Response rates with and without previous treatment were 18.2% and 50%, respectively. Median progression-free survival was 17.3 months. The main hematologic toxicities were leukopenia (22.6%) and neutropenia (45.2%). No treatment-related deaths occurred. Conclusion: Our modified Saltz regimen exhibited sufficient efficacy, feasibility, and manageable toxicity as a therapeutic option for selected colorectal cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84858700540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858700540&partnerID=8YFLogxK

U2 - 10.1007/s12325-012-0002-3

DO - 10.1007/s12325-012-0002-3

M3 - Article

C2 - 22351434

AN - SCOPUS:84858700540

VL - 29

SP - 287

EP - 296

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 3

ER -